PharmaResources (Shanghai) Co. Ltd. A (301230) - Net Assets
Based on the latest financial reports, PharmaResources (Shanghai) Co. Ltd. A (301230) has net assets worth CN¥1.03 Billion CNY (≈ $150.71 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.32 Billion ≈ $192.55 Million USD) and total liabilities (CN¥285.89 Million ≈ $41.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See 301230 equity financing ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.03 Billion |
| % of Total Assets | 78.27% |
| Annual Growth Rate | 30.72% |
| 5-Year Change | 188.21% |
| 10-Year Change | N/A |
| Growth Volatility | 86.66 |
PharmaResources (Shanghai) Co. Ltd. A - Net Assets Trend (2020–2025)
This chart illustrates how PharmaResources (Shanghai) Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see PharmaResources (Shanghai) Co. Ltd. A market cap and net worth.
Annual Net Assets for PharmaResources (Shanghai) Co. Ltd. A (2020–2025)
The table below shows the annual net assets of PharmaResources (Shanghai) Co. Ltd. A from 2020 to 2025. Also explore 301230 net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.00 Billion ≈ $146.95 Million |
-2.76% |
| 2024-12-31 | CN¥1.03 Billion ≈ $151.12 Million |
-7.59% |
| 2023-12-31 | CN¥1.12 Billion ≈ $163.53 Million |
+0.42% |
| 2022-12-31 | CN¥1.11 Billion ≈ $162.85 Million |
+219.39% |
| 2021-12-31 | CN¥348.44 Million ≈ $50.99 Million |
+32.40% |
| 2020-12-31 | CN¥263.18 Million ≈ $38.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PharmaResources (Shanghai) Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 80.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥109.84 Million | 10.94% |
| Other Components | CN¥894.39 Million | 89.06% |
| Total Equity | CN¥1.00 Billion | 100.00% |
PharmaResources (Shanghai) Co. Ltd. A Competitors by Market Cap
The table below lists competitors of PharmaResources (Shanghai) Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mako Mining Corp
V:MKO
|
$932.41 Million |
|
O-I Glass Inc
NYSE:OI
|
$932.71 Million |
|
Suzhou Hailu Heavy Industry Co Ltd
SHE:002255
|
$933.77 Million |
|
Equity Bancshares, Inc.
NYSE:EQBK
|
$933.79 Million |
|
Guararapes Confecções S.A
SA:GUAR3
|
$932.14 Million |
|
Dios Fastigheter AB
ST:DIOS
|
$932.10 Million |
|
Prodea Real Estate Investment Co.
AT:PRODEA
|
$931.94 Million |
|
Rongan Property Co Ltd
SHE:000517
|
$931.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmaResources (Shanghai) Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,032,697,458 to 1,004,230,108, a change of -28,467,350 (-2.8%).
- Net income of 34,294,767 contributed positively to equity growth.
- Dividend payments of 54,044,723 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥34.29 Million | +3.42% |
| Dividends Paid | CN¥54.04 Million | -5.38% |
| Other Changes | CN¥-8.72 Million | -0.87% |
| Total Change | CN¥- | -2.76% |
Book Value vs Market Value Analysis
This analysis compares PharmaResources (Shanghai) Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 14.03x to 6.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥2.51 | CN¥35.21 | x |
| 2021-12-31 | CN¥3.32 | CN¥35.21 | x |
| 2022-12-31 | CN¥7.95 | CN¥35.21 | x |
| 2023-12-31 | CN¥7.99 | CN¥35.21 | x |
| 2024-12-31 | CN¥7.40 | CN¥35.21 | x |
| 2025-12-31 | CN¥5.53 | CN¥35.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmaResources (Shanghai) Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.98%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.31x
- Recent ROE (3.42%) is below the historical average (9.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 18.50% | 17.21% | 0.76x | 1.42x | CN¥22.37 Million |
| 2021 | 21.12% | 16.42% | 0.80x | 1.60x | CN¥38.73 Million |
| 2022 | 6.04% | 14.03% | 0.37x | 1.17x | CN¥-44.11 Million |
| 2023 | 3.37% | 7.68% | 0.33x | 1.33x | CN¥-74.14 Million |
| 2024 | 1.65% | 3.14% | 0.41x | 1.27x | CN¥-86.19 Million |
| 2025 | 3.42% | 4.98% | 0.52x | 1.31x | CN¥-66.13 Million |
Industry Comparison
This section compares PharmaResources (Shanghai) Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,630,540,352
- Average return on equity (ROE) among peers: 6.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmaResources (Shanghai) Co. Ltd. A (301230) | CN¥1.03 Billion | 18.50% | 0.28x | $932.27 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $89.81 Million | 2.75% | 1.57x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $56.30 Million | 0.00% | 2.39x | $1.37 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $445.86 Million | 0.46% | 0.45x | $483.41 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $712.38 Million | 3.28% | 0.06x | $575.51 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.67 Billion | 2.43% | 1.21x | $1.61 Billion |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $3.46 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $1.10 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $25.90 Billion | 5.00% | 0.05x | $4.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.44 Billion | 2.86% | 0.17x | $428.14 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.62 Billion |
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturin… Read more